Applied Genetic Technologies Corp (NASDAQ:AGTC) rose 10.8% during trading on Tuesday . The company traded as high as $8.45 and last traded at $8.34, approximately 1,178,174 shares traded hands during trading. A decline of 80% from the average daily volume of 5,755,563 shares. The stock had previously closed at $7.53.

Several equities research analysts have recently commented on AGTC shares. Zacks Investment Research upgraded shares of Applied Genetic Technologies from a “sell” rating to a “hold” rating in a report on Tuesday, November 19th. BMO Capital Markets increased their price objective on shares of Applied Genetic Technologies from $9.00 to $16.00 and gave the company an “outperform” rating in a research note on Thursday, January 9th. TheStreet lowered shares of Applied Genetic Technologies from a “c-” rating to a “d” rating in a report on Monday, September 30th. ValuEngine downgraded shares of Applied Genetic Technologies from a “hold” rating to a “sell” rating in a research note on Monday. Finally, Wedbush reissued a “buy” rating and issued a $12.00 price objective on shares of Applied Genetic Technologies in a research note on Thursday, January 9th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $11.88.

The business has a 50-day moving average of $4.05 and a two-hundred day moving average of $3.58. The company has a market cap of $142.83 million, a P/E ratio of -75.82 and a beta of 2.71. The company has a debt-to-equity ratio of 0.08, a current ratio of 7.95 and a quick ratio of 7.95.

Applied Genetic Technologies (NASDAQ:AGTC) last announced its earnings results on Tuesday, November 12th. The biotechnology company reported ($0.64) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.58) by ($0.06). Applied Genetic Technologies had a negative return on equity of 19.02% and a negative net margin of 4.81%. Equities analysts anticipate that Applied Genetic Technologies Corp will post -2.37 EPS for the current fiscal year.

In other news, major shareholder Patrick Johan Hendrik Krol sold 81,162 shares of the firm’s stock in a transaction dated Thursday, December 26th. The shares were sold at an average price of $5.24, for a total value of $425,288.88. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 3.10% of the stock is currently owned by company insiders.

Several hedge funds have recently modified their holdings of AGTC. Millennium Management LLC purchased a new stake in shares of Applied Genetic Technologies during the 3rd quarter valued at $79,000. Squarepoint Ops LLC boosted its stake in Applied Genetic Technologies by 41.0% in the 3rd quarter. Squarepoint Ops LLC now owns 93,800 shares of the biotechnology company’s stock worth $390,000 after purchasing an additional 27,274 shares in the last quarter. Wedbush Securities Inc. purchased a new stake in Applied Genetic Technologies during the 3rd quarter worth approximately $304,000. Colony Group LLC purchased a new stake in Applied Genetic Technologies during the 2nd quarter worth approximately $610,000. Finally, D. E. Shaw & Co. Inc. increased its stake in Applied Genetic Technologies by 21.7% during the 2nd quarter. D. E. Shaw & Co. Inc. now owns 57,902 shares of the biotechnology company’s stock valued at $219,000 after purchasing an additional 10,329 shares in the last quarter. 44.88% of the stock is currently owned by institutional investors and hedge funds.

Applied Genetic Technologies Company Profile (NASDAQ:AGTC)

Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. The company's lead products consist of four ophthalmology development programs across three targets, including X-linked retinoschisis that is in Phase I/II clinical trials; X-linked retinitis pigmentosa, which is in Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials for the treatment of inherited retinal diseases, as well as a preclinical program in adrenoleukodystrophy, which is a disease of the central nervous system and otology.

Further Reading: Understanding debt-to-equity ratio in fundamental analysis

Receive News & Ratings for Applied Genetic Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Genetic Technologies and related companies with MarketBeat.com's FREE daily email newsletter.